Results 301 to 310 of about 17,182,321 (391)

781 CHRONIC TRANSFUSION THERAPY IN SICKLE CELL ANEMIA (SSA) USING DONORS MATCHED FOR MINOR RBC ANTIGENS [PDF]

, 1981
Daniel R. Ambruso, John H. Githens, Roosevelt Alcorn, W M Vaughn, Taru Hays, Stephen F. Wallner   +5 more
openalex   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source

Future of cell therapy

Annals of Physical and Rehabilitation Medicine, 2014
openaire   +2 more sources

Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution. [PDF]

Blood Adv
Riedel A, Phely L, Hug S, Faustmann P, Schroeder JC, Besemer B, Paczulla Stanger AM, Faul C, Lengerke C, Weller JF, Bethge W.   +10 more
europepmc   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Mathematical Modeling of the CAR T-cell Therapy [PDF]

, 2020
Elliott, Samantha, Kose, Emek, Zollinger, Elizabeth   +2 more
core   +1 more source

A Macrophage-Based Cell Therapy Approach Promotes Collagen Deposition in Diabetic Wounds. [PDF]

Wound Repair Regen
Boodhoo K, Vlok M, van de Vyver M.
europepmc   +1 more source

Endoglin mediates the tumor‐ and metastasis‐promoting traits of stromal myofibroblasts in human breast carcinomas

Molecular Oncology, EarlyView.
Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo, Yoshihiro Mezawa, Zixu Wang, Ahmet Acar, Yasuhiko Ito, Atsushi Takano, Yohei Miyagi, Tomoyuki Yokose, Toshinari Yamashita, Yataro Daigo, Takuya Shirakihara, Akira Orimo   +11 more
wiley   +1 more source

Adoptive immune cell therapy for colorectal cancer. [PDF]

Front Immunol
Liu C, Liu N, Zhang T, Tu Y.
europepmc   +1 more source

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

Molecular Oncology, EarlyView.
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley   +1 more source